nach oben

Erschienen in:

2019 | OriginalPaper | Buchkapitel

29. Lyphmknotenmetastasen bei unbekanntem Primärtumor

verfasst von : Prof. Dr. Christoph Röcken

Erschienen in: Pathologie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Lymphknotenmetastasen sind eine häufige Ursache für die Durchführung von Lymphknotenbiopsien. Dieses Kapitel behandelt die Strategien für die Abklärung des sog. CUP(carcinoma of unknown primary)-Syndroms. Klinische Befunde und Lymphknotenlokalisation begründen den Einsatz einer differentiellen immunhistochemischen und molekularen Diagnostik, wobei in der Differenzialdiagnostik auch die Abgrenzung zu entzündlich überlagerten Lymphomen und nicht epithelialen Tumoren bedeutsam ist.

Blaustein’s Pathology of the Female Genital Tract (2011) Springer, New York

Quick Reference Handbook for Surgical Pathologists (2011) Springer, New York

Agaimy A, Erlenbach-Wunsch K, Konukiewitz B et al (2013) ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin. Mod Pathol 26:995–1003CrossRefPubMed

Agoff SN, Lamps LW, Philip AT et al (2000) Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 13:238–242CrossRefPubMed

Barr ML, Jilaveanu LB, Camp RL et al (2015) PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma? J Clin Pathol 68:12–17CrossRefPubMed

Bellizzi AM (2013) Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry. Adv Anat Pathol 20:285–314CrossRefPubMed

Brewster DH, Lang J, Bhatti LA et al (2014) Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961–2010. Cancer Epidemiol 38:227–234CrossRefPubMed

Byrd-Gloster AL, Khoor A, Glass LF et al (2000) Differential expression of thyroid transcription factor 1 in small cell lung carcinoma and Merkel cell tumor. Hum Pathol 31:58–62CrossRefPubMed

Chen ZE, Lin F (2015) Application of immunohistochemistry in gastrointestinal and liver neoplasms: new markers and evolving practice. Arch Pathol Lab Med 139:14–23CrossRefPubMed

10.

Chu PG, Weiss LM (2002) Keratin expression in human tissues and neoplasms. Histopathology 40:403–439CrossRefPubMed

11.

Conner JR, Hornick JL (2015) Metastatic carcinoma of unknown primary: diagnostic approach using immunohistochemistry. Adv Anat Pathol 22:149–167CrossRefPubMed

12.

Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147CrossRefPubMed

13.

Egberts F, Bergner I, Krüger S et al (2014) Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. Ann Oncol 25:246–250CrossRefPubMed

14.

Egberts F, Krüger S, Behrens HM et al (2014) Melanomas of unknown primary frequently harbor TERT-promoter mutations. Melanoma Res 24:131–136CrossRefPubMed

15.

Fizazi K, Greco FA, Pavlidis N et al (2015) Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 26(Suppl 5):v133–v138CrossRefPubMed

16.

Greco FA, Lennington WJ, Spigel DR, Hainsworth JD (2013) Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst 105:782–790CrossRefPubMed

17.

Hainsworth JD, Greco FA (2014) Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care. Virchows Arch 464:393–402CrossRefPubMed

18.

Hainsworth JD, Rubin MS, Spigel DR et al (2013) Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 31:217–223CrossRefPubMed

19.

Klöppel G (2015) Neoplasien des disseminierten neuroendokrine Zellsystems des Gastrointestinaltrakts. Pathologe 36:237–245CrossRefPubMed

20.

Köbel M, Bak J, Bertelsen BI et al (2014) Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 64:1004–1013CrossRefPubMed

21.

Koo J, Zhou X, Moschiano E et al (2013) The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin. Endocr Pathol 24:184–190CrossRefPubMed

22.

Liu H, Shi J, Wilkerson ML, Lin F (2012) Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol 138:57–64CrossRefPubMed

23.

Miettinen M, McCue PA, Sarlomo-Rikala M et al (2014) GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol 38:13–22CrossRefPubMedCentralPubMed

24.

Moll R, Divo M, Langbein L (2008) The human keratins: biology and pathology. Histochem Cell Biol 129:705–733CrossRefPubMedCentralPubMed

25.

Ordonez NG (2012) Value of PAX 8 immunostaining in tumor diagnosis: a review and update. Adv Anat Pathol 19:140–151CrossRefPubMed

26.

Pavlidis N, Briasoulis E, Hainsworth J, Greco FA (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990–2005CrossRefPubMed

27.

Pavlidis N, Fizazi K (2009) Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 69:271–278CrossRefPubMed

28.

Pavlidis N, Pentheroudakis G (2012) Cancer of unknown primary site. Lancet 379:1428–1435CrossRefPubMed

29.

Saad RS, Ghorab Z, Khalifa MA, Xu M (2011) CDX2 as a marker for intestinal differentiation: Its utility and limitations. World J Gastrointest Surg 3:159–166CrossRefPubMedCentralPubMed

30.

Tetzlaff MT, Torres-Cabala CA, Pattanaprichakul P et al (2015) Emerging clinical applications of selected biomarkers in melanoma. Clin Cosmet Investig Dermatol 8:35–46PubMedPubMedCentral

31.

Yamaguchi T, Hosono Y, Yanagisawa K, Takahashi T (2013) NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression. Cancer Cell 23:718–723CrossRefPubMed

32.

Yao JC, Hassan M, Phan A et al (2008) One hundred years after „carcinoid“: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072CrossRefPubMed

33.

Zheng R, Blobel GA (2010) GATA transcription factors and cancer. Genes Cancer 1:1178–1188CrossRefPubMedCentralPubMed

Titel: Lyphmknotenmetastasen bei unbekanntem Primärtumor
verfasst von: Prof. Dr. Christoph Röcken
Verlag: Springer Berlin Heidelberg
Buch: Pathologie
Print ISBN: 978-3-540-85183-7

Electronic ISBN: 978-3-540-85184-4

Copyright-Jahr: 2019
DOI: https://doi.org/10.1007/978-3-540-85184-4_29

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

29. Lyphmknotenmetastasen bei unbekanntem Primärtumor

Zusammenfassung

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie